Dicarboxylic acid to prevent acute kidney injury
Dicarboxylic acid therapy for prevention of kidney injury
This project is trying a dicarboxylic acid to protect hospitalized people from sudden (acute) kidney injury.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11190863 on NIH RePORTER |
What this research studies
If I'm at risk of kidney damage while in the hospital, this work is exploring whether giving a dicarboxylic acid can protect my kidney cells by boosting a different fat-processing pathway called peroxisomal fatty acid oxidation. Researchers will run lab and preclinical experiments and link those findings to human samples or clinical situations to see if the approach prevents early tubular damage. The aim is to stop acute injury and lower my long-term risk of developing chronic kidney disease after an episode of acute kidney injury. If the results look promising, the approach could move toward clinical testing at hospitals like the University of Pittsburgh.
Who could benefit from this research
Good fit: Ideal candidates would be hospitalized adults at high risk for acute kidney injury—such as critically ill patients, those with sepsis, or people undergoing major surgery—especially at participating centers.
Not a fit: People with long-standing end-stage kidney disease on dialysis or whose kidney damage is already irreversible are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, this could reduce hospital-acquired acute kidney injury and lower the chance of progressing to chronic kidney disease.
How similar studies have performed: Most prior kidney-protection work targeted mitochondria, and boosting peroxisomal fatty acid oxidation is a newer, mostly preclinical approach with limited human data so far.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Sims-Lucas, Sunder — University of Pittsburgh at Pittsburgh
- Study coordinator: Sims-Lucas, Sunder
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.